Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
NCT04771299 · Lakshmi N Yatham · PHASE3 · terminated · last registry update 2024-10-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Research support no longer available.” | – | Registry record, Lakshmi N Yatham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-21Also stopped (terminated): Alexza Pharmaceuticals, Inc., Apomorphine Cartridge (NCT05979415)
- 2025-10-20Results posted on the registry: AbbVie, Cariprazine + Placebo (NCT05368558)
- 2025-10-20Also stopped (terminated): AbbVie, Cariprazine + Placebo (NCT05368558)
- 2025-10-06Phase 3 first posted: Affiliated Hospital of Qinghai University, Olanzapine + Metoclopramide (NCT07208305)
- 2025-09-25Results posted on the registry: University of Rochester NCORP Research Base, Dexamethasone + Netupitant/Palonosetron Hydrochloride (NCT03367572)
- 2025-09-22Results posted on the registry: Massachusetts General Hospital, Pramipexole + Placebo (NCT04759703)
- 2025-09-22Also stopped (terminated): Massachusetts General Hospital, Pramipexole + Placebo (NCT04759703)
- 2025-08-28Results posted on the registry: Boehringer Ingelheim, Pramipexole manufactured in Ingelheim + Pramipexole manufactured in Ennigerloh (NCT06457204)
- 2025-07-29Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, Haloperidol + Metoclopramide 10mg (NCT02098499)
- 2025-06-25Phase 3 first posted: Shanghai Children's Medical Center, Olanzapine Tablets + Placebo (NCT07035821)
- 2025-06-24Also stopped (terminated): Third People's Hospital, Huzhou City, Zhejiang Province, China, a drug against DRD3 (NCT06949657)
- 2025-06-18Results posted on the registry: University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2025-06-18Also stopped (terminated): University of Michigan Rogel Cancer Center, Ondansetron + Dexamethasone (NCT04503668)
- 2025-06-06Phase 3 first posted: Md. Moktadirul Hoque Shuvo, Tablet Amitriptyline 10 milligrams + Tablet Trifluoperazine 1 milligrams twice daily (NCT07008235)
- 2025-05-21Results posted on the registry: Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-05-21Also stopped (terminated): Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2025-05-01Phase 3 first posted: Jiuda Zhao, standard quadruple antiemetic therapy + standard quadruple antiemetic therapy (NCT06952920)
- 2025-03-26Results posted on the registry: Minerva Neurosciences, Roluperidone 64 mg + Olanzapine 10 MG (NCT06107803)
- 2025-02-27Phase 3 first posted: Mahidol University, olanzapine + Placebo (NCT06850454)
- 2024-12-27Also stopped (terminated): Central Institute of Mental Health, Mannheim, Cannabidiol + Olanzapine (NCT02088060)
- 2024-12-10Results posted on the registry: National Cancer Institute (NCI), LMP744 (NCT03030417)
- 2024-12-05Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, olanzapine and melatonin (NCT00512070)
- 2024-11-20Results posted on the registry: Christine Oryhan, Opioid Anesthetics + Non Opioid Analgesics (NCT04081545)
- 2024-10-23Results posted on the registry: University of New Mexico, Pramipexole Oral Tablet (NCT03842709)
- 2024-10-21Results posted on the registry: Technical University of Munich, Olanzapine or amisulpride (NCT01029769)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision